{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:09:13Z","timestamp":1777928953052,"version":"3.51.4"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Am Assoc Nurse Pract"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title>Background and purpose:<\/jats:title>\n            <jats:p>In the past decade, there has been much advancement in oral antidiabetic agents, but few changes in insulin therapy. With the addition of the ultra-long-acting insulins, insulin glargine U300 (IGlar 300) and insulin degludec (IDeg 100 and IDeg 200), it is important to understand key aspects in the agents' clinical properties, efficacy, safety, dosing, packaging, and place in therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A literature review was conducted using PubMed database and was limited to English, full-text articles published from January 2000 to January 2018. The following search terms were used: insulin glargine 300, insulin degludec, Toujeo, Tresiba, and ultra-long-acting insulin.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>These agents are longer acting with sustained insulin coverage as compared with other basal insulins while having a low potential for hypoglycemia. Efficacy and safety profiles are quite good, and potential for weight gain was similar to IGlar 100.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Implications for practice:<\/jats:title>\n            <jats:p>Depending on the patient's needs, these newer agents may offer some advantages. Insulin glargine U300 and IDeg 200 are concentrated, allowing for administration of large doses by less volume, thereby theoretically improving absorption. For patients needing flexible dosing, IDeg may be beneficial. The ultra-long-acting agents may also be useful if it is suspected that the basal insulin is not lasting the entire day.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/jxx.0000000000000076","type":"journal-article","created":{"date-parts":[[2018,7,4]],"date-time":"2018-07-04T04:17:05Z","timestamp":1530677825000},"page":"373-380","source":"Crossref","is-referenced-by-count":10,"title":["Ultra-long-acting insulins: A review of efficacy, safety, and implications for practice"],"prefix":"10.1097","volume":"30","author":[{"given":"Courtney S.","family":"Davis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua W.","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott S.","family":"Malinowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meagan A.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie W.","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230821","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2337\/cd17-0119","article-title":"Standards of medical care in diabetes\u20142018 abridged for primary Care providers","volume":"36","year":"2018","journal-title":"Clinical Diabetes"},{"key":"R2-20230821","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1464-5491.2006.01913.x","article-title":"Twice-daily compared with once-daily insulin glargine in people with type 1 diabetes using meal-time insulin aspart","volume":"23","author":"Ashwell","year":"2006","journal-title":"Diabetic Medicine"},{"key":"R3-20230821","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2337\/dc14-0006","article-title":"New insulin glargine 300 Units\/mL provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units\/mL","volume":"38","author":"Becker","year":"2015","journal-title":"Diabetes Care"},{"key":"R4-20230821","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2337\/dc16-0684","article-title":"Comparison of insulin glargine 300 Units\/mL and 100 Units\/mL in adults with type 1 Diabetes: Continuous glucose monitoring profiles and variability using morning or evening injections","volume":"40","author":"Bergenstal","year":"2017","journal-title":"Diabetes Care"},{"key":"R5-20230821","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/dme.12243","article-title":"Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN \u00ae basal-bolus type 1): 2-year results of a randomized clinical trial","volume":"30","author":"Bode","year":"2013","journal-title":"Diabetic Medicine"},{"key":"R6-20230821","doi-asserted-by":"crossref","first-page":"785","DOI":"10.4158\/EP13411.OR","article-title":"Efficacy and safety of insulin degludec 200 U\/mL and insulin degludec 100 U\/mL in patients with type 2 diabetes (Begin: Compare)","volume":"20","author":"Bode","year":"2014","journal-title":"Endocrine Practice"},{"key":"R7-20230821","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.diabet.2017.04.007","article-title":"Glycaemic control and hypoglycaemia with insulin glargine 300 U\/mL versus insulin glargine 100 U\/mL in insulin- naive people with type 2 diabetes: 12-month results from the EDITION 3 trial","volume":"43","author":"Bolli","year":"2017","journal-title":"Diabetes & Metabolism"},{"key":"R8-20230821","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/dom.12438","article-title":"New insulin glargine 300 U\/ml compared with glargine 100 U\/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: A randomized controlled trial (EDITION 3)","volume":"17","author":"Bolli","year":"2015","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"R9-20230821","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.2337\/dci15-0023","article-title":"Insulin's role in diabetes management: After 90 years, still considered the essential \u201cblack dress\u201d","volume":"38","author":"Cefalu","year":"2015","journal-title":"Diabetes Care"},{"key":"R11-20230821","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2147\/TCRM.S99855","article-title":"Concentrated insulins: The new basal insulins","volume":"12","author":"Davis","year":"2016","journal-title":"Therapeutics and Clinical Risk Management"},{"key":"R12-20230821","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.2147\/PPA.S92123","article-title":"Insulin glargine 300U\/ml in the management of diabetes: Clinical utility and patient perspectives","volume":"10","author":"de Galan","year":"2016","journal-title":"Patient Preference and Adherence"},{"key":"R52-20230821","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.2337\/dc11-0721","article-title":"Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects","volume":"34","author":"de la Pena","year":"2011","journal-title":"Diabetes Care"},{"key":"R13-20230821","doi-asserted-by":"crossref","first-page":"e009421","DOI":"10.1136\/bmjopen-2015-009421","article-title":"Safety and efficacy of insulin glargine 300 u\/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: A network meta-analysis","volume":"6","author":"Freemantle","year":"2016","journal-title":"BMJ Open"},{"key":"R14-20230821","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(12)60205-0","article-title":"Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN basal-bolus type 2): A phase 3, randomised, open-label, treat-to-target non-inferiority trial","volume":"379","author":"Garber","year":"2012","journal-title":"Lancet"},{"key":"R15-20230821","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.2337\/dc12-2329","article-title":"Low-volume insulin degludec 200 Units\/mL once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes","volume":"36","author":"Gough","year":"2013","journal-title":"Diabetes Care"},{"key":"R16-20230821","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/1753-0407.12266","article-title":"Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action","volume":"8","author":"Heise","year":"2016","journal-title":"Journal of Diabetes"},{"key":"R17-20230821","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/j.1463-1326.2012.01638.x","article-title":"Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes","volume":"14","author":"Heise","year":"2012","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"R18-20230821","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(12)60204-9","article-title":"Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN basal-bolus type 1): A phase 3, randomised, open-label, treat-to-target non-inferiority trial","volume":"379","author":"Heller","year":"2012","journal-title":"Lancet"},{"key":"R19-20230821","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc15-0249","article-title":"New insulin glargine 300 Units\/mL versus glargine 100 Units\/mL in people with type 1 diabetes: A randomized, phase 3a, open-label clinical trial (EDITION 4)","volume":"38","author":"Home","year":"2015","journal-title":"Diabetes Care"},{"key":"R20-20230821","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/dom.13048","article-title":"Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U\/mL versus glargine 100 U\/mL in people with type 1 diabetes (EDITION 4)","volume":"20","author":"Home","year":"2018","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"R21-20230821","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1007\/s11095-012-0739-z","article-title":"Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin","volume":"29","author":"Jonassen","year":"2012","journal-title":"Pharmaceutical Research"},{"key":"R22-20230821","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/jdi.12502","article-title":"Efficacy and safety of once-daily insulin degludec dosed flexibly at convenient times vs fixed dosing at the same time each day in a Japanese cohort with type 2 diabetes: A randomized, 26-week, treat-to-target trial","volume":"7","author":"Kadowaki","year":"2016","journal-title":"Journal of Diabetes Investigation"},{"key":"R23-20230821","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2147\/DMSO.S54953","article-title":"Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes","volume":"8","author":"Kerlan","year":"2015","journal-title":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy"},{"key":"R24-20230821","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40262-013-0113-2","article-title":"Insulin degludec: Pharmacokinetics in patients with renal impairment","volume":"53","author":"Kiss","year":"2014","journal-title":"Clinical Pharmacokinetics"},{"key":"R25-20230821","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s40261-013-0096-7","article-title":"A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U\/mL formulations of ultra-long-acting insulin degludec","volume":"33","author":"Korsatko","year":"2013","journal-title":"Clinical Drug Investigation"},{"key":"R26-20230821","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40266-013-0138-0","article-title":"Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus","volume":"31","author":"Korsatko","year":"2014","journal-title":"Drugs & Aging"},{"key":"R27-20230821","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40261-013-0154-1","article-title":"Insulin degludec: Pharmacokinetic properties in subjects with hepatic impairment","volume":"34","author":"Kup\u010dov\u00e1","year":"2014","journal-title":"Clinical Drug Investigation"},{"key":"R28-20230821","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2337\/db14-0930","article-title":"Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 Years of follow-up in the DCCT\/EDIC","volume":"64","author":"Lachin","year":"2015","journal-title":"Diabetes"},{"key":"R29-20230821","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4158\/EP.15.1.71","article-title":"High-dose insulin therapy: Is it time for U-500 insulin?","volume":"15","author":"Lane","year":"2009","journal-title":"Endocrine Practice"},{"key":"R31-20230821","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1210\/jc.2012-3249","article-title":"Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): A 26-week randomized, treat-to-target trial with a 26-week extension","volume":"98","author":"Mathieu","year":"2013","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"key":"R32-20230821","doi-asserted-by":"crossref","first-page":"858","DOI":"10.2337\/dc12-1668","article-title":"The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individ","volume":"36","author":"Meneghini","year":"2013","journal-title":"Diabetes Care"},{"key":"R33-20230821","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s12325-013-0036-1","article-title":"Insulin degludec once-daily in type 2 diabetes: Simple or step-wise titration (BEGIN: once simple use)","volume":"30","author":"Philis-Tsimikas","year":"2013","journal-title":"Advances in Therapy"},{"key":"R34-20230821","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.clinthera.2006.10.020","article-title":"Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes","volume":"28","author":"Philis-Tsimikas","year":"2006","journal-title":"Clinical Therapeutics"},{"key":"R36-20230821","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1089\/dia.2015.0290","article-title":"Efficacy and safety of flexible versus fixed dosing intervals of insulin glargine 300 U\/mL in people with type 2 diabetes","volume":"18","author":"Riddle","year":"2016","journal-title":"Diabetes Technology & Therapeutics"},{"key":"R37-20230821","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.2337\/dc14-0991","article-title":"New insulin glargine 300 Units\/mL versus glargine 100 Units\/mL in people with type 2 diabetes using basal and mealtime insulin: Glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1)","volume":"37","author":"Riddle","year":"2014","journal-title":"Diabetes Care"},{"key":"R38-20230821","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/dom.12472","article-title":"One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U\/ml compared with 100 U\/ml in people with type 2 diabetes using basal plus meal-time insulin: The EDITION 1 12-month randomized trial, including 6-month extension","volume":"17","author":"Riddle","year":"2015","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"R39-20230821","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/dme.12303","article-title":"Comparison of insulin degludec with insulin glargine in insulin-naive subjects with type 2 diabetes: A 2-year randomized, treat-to-target trial","volume":"30","author":"Rodbard","year":"2013","journal-title":"Diabetic Medicine"},{"key":"R40-20230821","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.2146\/ajhp090554","article-title":"Use of concentrated insulin human regular (U-500) for patients with diabetes","volume":"67","author":"Segal","year":"2010","journal-title":"American Journal of Health-System Pharmacy"},{"key":"R41-20230821","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/dom.12283","article-title":"Investigational new insulin glargine 300 U\/ml has the same metabolism as insulin glargine 100 U\/ml","volume":"16","author":"Steinstraesser","year":"2014","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"R42-20230821","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.2337\/dc09-2294","article-title":"A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs","volume":"33","author":"Swinnen","year":"2010","journal-title":"Diabetes Care"},{"key":"R45-20230821","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.diabres.2015.04.002","article-title":"Clinical use of insulin degludec","volume":"109","author":"Vora","year":"2015","journal-title":"Diabetes Research and Clinical Practice"},{"key":"R46-20230821","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2147\/DMSO.S87873","article-title":"rDNA insulin glargine U300\u2014a critical appraisal","volume":"9","author":"Wang","year":"2016","journal-title":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy"},{"key":"R48-20230821","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/dom.12532","article-title":"Glycaemic control and hypoglycaemia with new insulin glargine 300 U\/ml versus insulin glargine 100 U\/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: The EDITION 2 randomized 12-month trial including 6-month extension","volume":"17","author":"Yki-J\u00e4rvinen","year":"2015","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"R49-20230821","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.2337\/dc14-0990","article-title":"New insulin glargine 300 Units\/mL versus glargine 100 Units\/mL in people with type 2 diabetes using oral agents and basal insulin: Glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2)","volume":"37","author":"Yki-J\u00e4rvinen","year":"2014","journal-title":"Diabetes Care"},{"key":"R50-20230821","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.2337\/diacare.23.8.1130","article-title":"Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901\/3002 Study Group","volume":"23","author":"Yki-Jarvinen","year":"2000","journal-title":"Diabetes Care"},{"key":"R51-20230821","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.2337\/dc12-1205","article-title":"Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: A 1-year, randomized, treat-to-target trial (BEGIN once long)","volume":"35","author":"Zinman","year":"2012","journal-title":"Diabetes Care"}],"container-title":["Journal of the American Association of Nurse Practitioners"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01741002-201807000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T09:21:22Z","timestamp":1692609682000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01741002-201807000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/jxx.0000000000000076","relation":{},"ISSN":["2327-6924"],"issn-type":[{"value":"2327-6924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7]]}}}